New treatments of malignant lymphoma - A review;Neuere medikamente in der lymphomtherapie - Eine übersicht

Therapeutische Umschau

Volumn 67, Issue 10, 2010, Pages 537-543

  Mark, Michael ^a   Cerny, Thomas ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BELINOSTAT; BENDAMUSTINE; BEVACIZUMAB; BIOVAXID; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEFOROLIMUS; DOXORUBICIN; EPRATUZUMAB; EVEROLIMUS; FLUDARABINE; GALIXIMAB; IBRITUMOMAB TIUXETAN; LENALIDOMIDE; MABCAMPTH; MAPATUMUMAB; OFATUMUMAB; PANOBINOSTAT; PRALATREXATE; PREDNISONE; RAPAMYCIN; RITUXIMAB; ROMIDEPSIN; SGN 30; SGN 40; TEMSIROLIMUS; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELTUZUMAB; VINCRISTINE; VORINOSTAT;

B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DRUG EFFICACY; HUMAN; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PNEUMOCYSTIS PNEUMONIA; RADIOIMMUNOTHERAPY; REVIEW; TREATMENT RESPONSE;

ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; HISTONE DEACETYLASE INHIBITORS; HUMANS; LYMPHOMA; NEOPLASM STAGING; RADIOIMMUNOTHERAPY;

EID: 77958198678     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930/a000090     Document Type: Review

References (25)

1. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-97.
2. Fanale MA, Younes A. Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma. Drugs 2007; 67: 333-50. (Pubitemid 46425549)
3. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 235-42.
4. Briones J. Emerging therapies for B-cell non-Hodgkin lymphoma. Expert Rev Anticancer Ther 2009; 9: 1305-16.
5. Witzig TE, Flinn IW, Gordon LI et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262-9.
6. Cerveny CG, Law CL, McCormick RS et al. The anti-CD30 monoclonal antibody SGN-30 inhibits Hodgkin's disease growth and sensitizes cells to established chemotherapeutics [abstract no. 2639]. American Society of Hematology Annual Meeting abstracts. Blood 2004; 104: 2639.
7. Bartlett NL, Bernstein SH, Leonard JP et al. Antitumor activity and pharmacokinetics of six weekly doses of SGN-30 (anti-CD30 monoclonal antibody) in patients with refractory or recurrent CD30 + hematologic malignancies [abstract no. 2390]. Blood 2003; 102: 647a.
8. Ansell SM, Byrd JC, Horwitz SM et al. Phase I/II, open-label, dose-escalating study of MDX-060 administered weekly for 4 weeks in subjects with refractory/relapsed CD30 positive lymphoma [abstract no. 2636]. Blood 2004; 104: 721a.
9. Advani RH, Furman RR, Rosenblatt JD et al. Phase I study of humanized anti-CD40 immunotherapy with SGN-40 in non-Hodgkin's lymphoma [abstract no. 1504]. Blood 2005; 106: 433a.
10. Lugman M, Tong X, Niu X et al. CHIR-12.12, an antagonist anti-CD40 antibody, exhibits greater ADCC than rituximab against a variety of malignant B cells: evaluation of FcyRIIIa polymorphism and ADCC response [abstract no. 1472]. Blood 2005; 106: 424a.
11. Younes A, Vose JM, Zelenetz AD et al. Results of a phase 2 trial of HGSETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non Hodgkin's Lymphoma [abstract no. 489]. Blood 2005; 106: 146a.
12. Czuczman MS, Maddipatia S, Knight J et al. In vitro synergistic anti-tumor activity by targeting TRAIL-R1 and CD20 antigen by combining HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) and rituximab monoclonal antibody against non Hodgkin's lymphoma cells (NHL) [abstract no. 1475]. Blood 2005; 106: 425a.
13. Dennie TW, Kolesar JM. Bendamustine for the Treatment of Chronic Lymphocytic Leukemia and Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma. Clinical Therapeutics 2009; 31: 2290-311.
14. Fischer K et al. Bendamustine Combined with Rituximab (BR) in First-Line-Therapy of Advanced CLL: A Multicenter Phase II Trial of the German CLL Study Group (GCLLSG). Blood 2009; 114: oral presentation and abstract 205.
15. Rummel MJ et al. Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 114: oral presentation and abstract 405.
16. Tay K, Dunleavy K, Wilson WH. Novel agents for B-cell non-Hodgkin lymphoma: Science and the promise. Blood Reviews 2010; 24: 69-82.
17. Duvic M, Talpur R, Ni X et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109: 31-9.
18. Olsen EA, Kim YH, Kuzel TM et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 3109-15.
19. Piekarz R, Frye R, Wright J. Update of the NCI multiinstitutional phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-cell lymphoma. J Clin Oncol 2007; 25(Suppl 18): 8027. Abstract.
20. Gimsing P, Hansen M, Knudsen LM et al. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol 2008; 81: 170-6.
21. Ellis L, Pan Y, Smyth GK et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous Tcell lymphoma. Clin Cancer Res 2008 ;14: 4500-10.
22. Duvic M, Becker JC, Dalle S. Phase II trial of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma (CTCL). Blood2008; 112: 1005. Abstract.
23. Schuster SJ et al. Idiotyp vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trials. Presented at the 45th Annual Meeting of the American Society of Clinical Oncology; May-June 2009; Orlando, FL.
24. O'Connor OA, Horwitz S, Hamlin P et al. Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies. J Clin Oncol 2009; 27: 4357-64.
25. Hess G, Herbrecht R, Romaguera J et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 3822-9.